Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

FLORHAM PARK, N.J., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of its management team are scheduled to participate in the following investor conferences in November:

Guggenheim Securities 5th Annual Inflammation, Neurology & Immunology Conference in New York, NYDate: Tuesday, November 7, 2023Live Webcast: 2:30 p.m. ET Management to participate in one-on-one meetings throughout the conference

Jefferies London Healthcare Conference in London, EnglandDate: Tuesday, November 14, 2023Live Webcast: 10:30 a.m. ETManagement to participate in one-on-one meetings throughout the conference

Stifel 2023 Healthcare Conference in New York, NYDate: Wednesday, November 15, 2023Live Webcast: 2:25 p.m. ETManagement to participate in one-on-one meetings throughout the conference

Craig-Hallum 14th Annual Alpha Select Conference in New York, NYDate: Thursday, November 16, 2023Management to participate in one-on-one meetings throughout the conference

Evercore ISI 6th Annual HealthCONx Conference in Miami, FLDate: Wednesday, November 29, 2023Live Webcast: 4:15 p.m. ETManagement to participate in one-on-one meetings throughout the conference

To access the live webcast and archived recordings of each event, visit the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. Recordings will be available for 90 days following the conclusion of each meeting.

About Phathom Pharmaceuticals, Inc.Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB). For more information about Phathom, visit the Company’s website at www.phathompharma.com and follow the Company on LinkedIn and Twitter.

MEDIA CONTACTNick Benedetto1-877-742-8466[email protected]

INVESTOR CONTACTEric Sciorilli1-877-742-8466[email protected]

© 2023 Phathom Pharmaceuticals. All rights reserved.

Source: Phathom Pharmaceuticals

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Lerøy Seafood Group ASA: Primary Insider Transaction
• Dr. Ahlem Arfaoui Recognized with the Best Author on Election Law and Reform in New York of 2026 Award, Announces Release of The Power of the Political Contribution in the United States, a New Analysi
• Supreme Dental Clinic Announces Historic Colgate Collaboration as First Clinic in Mexico and Latin America